08.25.26 -- The Challenge Transferring Proprietary ADC Technology

Scale-out manufacturing speeds commercial launch by using modular single-use systems that preserve process consistency, reduce comparability risk, and align capacity with demand.

See how higher API activity is changing expectations around containment, scalability, and cross‑functional alignment — and why early decisions now have a greater impact on long‑term success.

Learn how biopharmaceutical leaders address scalability, quality control, and regulatory challenges when manufacturing protein-based therapies at commercial scale.

Complex biologics often outgrow traditional development platforms. Examine how an integrated development strategy can accelerate timelines while reducing risk.

Discover how a bispecific fusion nanobody (BFN) achieved BsAb titers above 7 g/L with 5 of 6 clones stable beyond 60 generations — from CLD through cGMP manufacturing.

Replace silos with a unified drug development approach to align earlier, improve handoffs, and reduce surprises through shared visibility and proactive coordination.

Early decisions can have long-lasting consequences for development timelines, cost, risk, and success. Engaging the appropriate disciplines early helps avoid downstream surprises and rework.

Middlesex County, NJ, is a premier life sciences hub, attracting major biopharma leaders, entrepreneurs, and investors to accelerate global medical innovation.

An automated RNA‑seq workflow maintains uniform gene‑expression profiles across wide RNA inputs, enabling consistent library quality and scalable genomics on standard liquid‑handling platforms.

Growing use of large‑volume subcutaneous therapies is increasing demand for wearable injectors that reduce user error, simplify preparation, and enhance safety through human‑factors‑focused design.

Find flexible scale-up from lab through commercial manufacturing, leveraging expertise. Gain technical insights for scalable, efficient development for advancing mRNA, saRNA, or circular RNA programs.

By working with a single supplier that can handle the entire manufacturing value chain, companies can reduce risk, improve flexibility, and accelerate their time to market.

Explore how controlled bioreactor environments enable optimization of critical process parameters and support robust, scalable AAV production from development through manufacturing.